Novavax, Inc. (NASDAQ:NVAX) shares, rose in value on Thursday, April 04, with the stock price up by 2.69% to the previous day’s close as strong demand from buyers drove the stock to $4.66.
Actively observing the price movement in the recent trading, the stock is buoying the session at $4.54. The value of beta (5-year monthly) is 1.60. Referring to stock’s 52-week performance, its high was $11.36, and the low was $3.53. On the whole, NVAX has fluctuated by -16.30% over the past month.
With the market capitalization of Novavax, Inc. currently standing at about $652.45 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.95, which is expected to increase to -$0.53 for fiscal year -$0.8 and then to about $0.12 by fiscal year 2025. Data indicates that the EPS growth is expected to be 85.20% in 2025, while the next year’s EPS growth is forecast to be 115.00%.
Analysts have estimated the company’s revenue for the quarter at $101.45 million, with a low estimate of $99.8 million and a high estimate of $104 million. According to the average forecast, sales growth in current quarter could jump up 25.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $849.66 million, representing a decrease of -13.60% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that NVAX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of NVAX currently trading nearly -6.37% and 0.60% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.21, while the 7-day volatility ratio is showing 5.03% which for the 30-day chart, stands at 6.42%. Furthermore, Novavax, Inc. (NVAX)’s beta value is 1.61, and its average true range (ATR) is 0.32.
A comparison of Novavax, Inc. (NVAX) with its peers suggests the former has fared considerably weaker in the market. NVAX showed an intraday change of 2.69% in today’s session so far, and over the past year, it shrunk by -37.00%%.
Data on historical trading for Novavax, Inc. (NASDAQ:NVAX) indicates that the trading volumes over the past 10 days have averaged 4.28 million and over the past 3 months, they’ve averaged 8.24 million. According to company’s latest data on outstanding shares, there are 139.51 million shares outstanding.
Nearly 5.82% of Novavax, Inc.’s shares belong to company insiders and institutional investors own 55.75% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 48.13 million shares as on Mar 15, 2024, resulting in a short ratio of 4.04. According to the data, the short interest in Novavax, Inc. (NVAX) stood at 34.39% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 54.83 million. The stock has fallen by -2.88% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NVAX stock heading into the next quarter.
